NEUWAY’s internal pipeline project may be partnered by co-development or complete asset transfer at different preclinical stages.


NEUWAY intends to combine partnered programs with its in-house pre-clinical development of CNS-related indications with high unmet medical need and orphan potential.

EnPC® provides the opportunity to bring drugs across the BBB that have demonstrated a valuable mechanism of action, but which eventually fail because they could not be successfully delivered to the brain.

Beside the focus on CNS-related projects NEUWAY is prepared to explore the application range of EnPCs® with external partners and to exploit potential USPs entrepreneurially.

Thus, EnPC® technology may be licensed out to enable third parties to add value to proprietary active pharmaceutical ingredient (API) provided by external partners.

NEUWAY has a flexible approach to deal structuring and aims to create relationships that maximize the value for both parties.

Please direct any inquiries to:

Dr. Heiko Manninga
Managing Director